• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by COMPASS Pathways Plc (Amendment)

    2/14/24 4:08:06 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email
    SC 13G/A 1 tm245955d10_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    COMPASS Pathways plc

    (Name of Issuer)

     

    Ordinary shares, nominal value £0.008 per share**

    (Title of Class of Securities)

     

    20451W101***

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** The Reporting Persons own ordinary shares through the Issuer’s American Depositary Shares, each representing one ordinary share.

     

    *** The ordinary shares have no CUSIP number. The CUSIP number for the Issuer’s American Depositary Shares, each representing one ordinary share, is 20451W101.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 9 Pages

     

     

    CUSIP No. 20451W101

     

    1.Names of Reporting Persons

     

    Paradigm BioCapital Advisors LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 3,425,988
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER  3,425,988
    8. SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,425,988

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.4%

     

    12.Type of Reporting Person (See Instructions)

     

    PN

     

    Page 2 of 9 Pages

     

     

    CUSIP No. 20451W101

     

    1.Names of Reporting Persons

     

    Paradigm BioCapital Advisors GP LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 3,425,988
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER  3,425,988
    8. SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,425,988 

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.4%

     

    12.Type of Reporting Person (See Instructions)

     

    OO

     

    Page 3 of 9 Pages

     

     

     

    CUSIP No. 20451W101

     

    1.Names of Reporting Persons

     

    Senai Asefaw, M.D.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    USA

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 3,425,988
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER  3,425,988
    8. SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,425,988 

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.4%

     

    12.Type of Reporting Person (See Instructions)

     

    IN

     

    Page 4 of 9 Pages

     

    CUSIP No. 20451W101

     

    1.Names of Reporting Persons

     

    Paradigm BioCapital International Fund Ltd.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)x

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH: 

    5. SOLE VOTING POWER 3,078,277
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER  3,078,277
    8. SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,078,277

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    4.9%

     

    12.Type of Reporting Person (See Instructions)

     

    CO 

     

    Page 5 of 9 Pages

     

     

    Item 1.

     

    (a) The name of the issuer is COMPASS Pathways plc (the “Issuer”).

     

    (b)The principal executive offices of the Issuer are located at 33 Broadwick Street, London W1F 0DQ, United Kingdom.

     

    Item 2.

     

    (a)This Schedule 13G is filed by the following (the “Reporting Persons”): (1) Paradigm BioCapital Advisors LP (the “Adviser”); (2) Paradigm BioCapital Advisors GP LLC (the “GP”); (3) Senai Asefaw, M.D. (“Senai Asefaw”), and (4) Paradigm BioCapital International Fund Ltd. (the “Fund”). The Fund is a private investment vehicle. The Fund and a separately managed account managed by the Adviser (the “Account”) directly beneficially own the Ordinary Shares (as defined below) reported in this Statement. The Adviser is the investment manager of the Fund and the Account. The GP is the general partner of the Adviser. Senai Asefaw is the managing member of the GP. The Adviser, the GP, and Senai Asefaw may be deemed to beneficially own the Ordinary Shares directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Ordinary Shares other than the Ordinary Shares directly beneficially owned by such Reporting Person.

     

    (b)The principal business office of the Reporting Persons is 767 Third Avenue, 17th Floor, New York, NY 10017.

     

    (c)For citizenship information see Item 4 of the cover page of each Reporting Person.

     

    (d)This statement relates to the ordinary shares, nominal value £0.008 per share, of the Issuer (the “Ordinary Shares”).

     

    (e)The Ordinary Shares have no CUSIP number. The CUSIP number for the Issuer’s American Depositary Shares, each representing one Ordinary Share, is 20451W101.

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);

     

    Page 6 of 9 Pages

     

      

    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) o Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:________________________

     

    Item 4. Ownership.

     

    See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the Event Date of this Schedule 13G/A1. Of the 3,425,988 Ordinary Shares reported, 3,078,277 are beneficially owned directly by the Fund (inclusive of 1,160,000 Ordinary Shares underlying warrants that are exercisable within 60 days), and 347,711 are beneficially owned directly by the Account.

     

    The percentages of beneficial ownership contained herein are based on: (x) 61,896,535 Ordinary Shares outstanding as of October 30, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 2, 2023; and (y) 1,160,000 Ordinary Shares underlying the warrants described above.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Page 7 of 9 Pages

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    (a)Not applicable.

     

    (b)Not applicable.

     

    (c)By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Paradigm BioCapital Advisors LP

    Paradigm BioCapital Advisors GP LLC

    Paradigm BioCapital International Fund Ltd.

     

    By: /s/ David K. Kim  

    Name: David K. Kim

    Title: Authorized Signatory

     

    /s/ Senai Asefaw, M.D.  

    Senai Asefaw, M.D.

     

     

    Page 9 of 9 Pages

     

    Get the next $CMPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    7/8/2026$21.00In-line → Outperform
    Evercore ISI
    5/22/2026Outperform
    Wolfe Research
    5/4/2026$18.00Buy
    Jefferies
    4/24/2026$17.00Buy
    B. Riley Securities
    12/10/2025$15.00Perform → Outperform
    Oppenheimer
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Karydas Daphne

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    5/29/26 5:31:43 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Santini Gino

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    5/29/26 5:26:52 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gover Justin D.

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    5/29/26 5:17:32 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

    Issued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. Tens of millions of adults live with major depressive disorder, and the majority never reach full remission on the first medication they try. That persistent treatment gap has drawn a wave of biotech and pharmaceutical companies into what is now one of the most closely watched races in interventional psychiatry, each pursuing a different way to reach patients that current antidepressants leave behind.

    7/21/26 9:00:00 AM ET
    $CMPS
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

    Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient CareNEW YORK, July 21, 2026 /CNW/ -- Market News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in patient outcomes due to new approaches introduced by pharmaceutical companies. Traditionally, treatments focused on boosting serotonin levels or other neurotransmitters, resulting in long waiting periods for patients to notice any changes, without any assurance of effectiveness. However, there is now a shift towards quicker-acting medications, exploration of new biological targets, and the development of perso

    7/21/26 8:30:00 AM ET
    $ATAI
    $CMPS
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

    Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarterUSA News Group News CommentaryNEW YORK, July 17, 2026 /CNW/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE:LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in

    7/17/26 8:50:00 AM ET
    $ATAI
    $CMPS
    $DFTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $CMPS
    SEC Filings

    View All

    COMPASS Pathways Plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - COMPASS Pathways plc (0001816590) (Filer)

    7/7/26 6:33:23 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by COMPASS Pathways Plc

    8-K - COMPASS Pathways plc (0001816590) (Filer)

    5/28/26 6:43:10 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by COMPASS Pathways Plc

    SCHEDULE 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    5/15/26 8:18:45 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    COMPASS Pathways upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded COMPASS Pathways from In-line to Outperform and set a new price target of $21.00

    7/8/26 9:59:55 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on COMPASS Pathways

    Wolfe Research initiated coverage of COMPASS Pathways with a rating of Outperform

    5/22/26 9:39:41 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on COMPASS Pathways with a new price target

    Jefferies initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $18.00

    5/4/26 8:34:35 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Financials

    Live finance-specific insights

    View All

    Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK)  Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NA

    5/6/26 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/698442687. The webcast will be archived for 30 days. About Compass Pathways Compass Pathw

    10/28/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:

    7/22/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Leadership Updates

    Live Leadership Updates

    View All

    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

    WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per

    6/29/26 7:30:00 AM ET
    $KLRA
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways Elects Kathleen Tregoning to Board of Directors

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. "With two successful Phase 3 trials meeting the primary endpoint, a

    5/28/26 6:30:00 AM ET
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

    4/29/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:35:16 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:20:24 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by COMPASS Pathways Plc

    SC 13G - COMPASS Pathways plc (0001816590) (Subject)

    4/11/24 4:04:21 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care